Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Oric Pharmaceuticals, Inc. ORIC

Healthcare  —  Biotechnology
13.16 (0.02) (0.15%) as of 25 Sep
Market cap
$1.4B
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Oric Pharmaceuticals, Inc. (ORIC) Business Profile

Updated before January 2025

Company Overview

Oric Pharmaceuticals, Inc. (ORIC) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies that target mechanisms of resistance in cancer treatment. Founded in 2014, ORIC is headquartered in South San Francisco, California. The company was co-founded by Dr. Charles Sawyers, a renowned oncologist and cancer researcher, and Dr. Scott Lowe, a leading expert in cancer biology. ORIC’s leadership team includes experienced executives and scientists with deep expertise in oncology drug development. The company is led by CEO Jacob Chacko, M.D., who brings a wealth of experience in the biopharmaceutical industry.

Core Business Segments

ORIC Pharmaceuticals focuses on developing therapies that address resistance mechanisms in cancer treatment. The company’s core business segments include:

1. Oncology Therapeutics

ORIC’s primary focus is on oncology therapeutics, with a pipeline of innovative drug candidates targeting resistance pathways in cancer. Key products and programs include:

  • ORIC-101: A glucocorticoid receptor antagonist being developed for the treatment of solid tumors in combination with other therapies.
  • ORIC-533: A small molecule inhibitor targeting CD73, which plays a role in immune suppression in the tumor microenvironment.
  • ORIC-944: A selective allosteric inhibitor of PRC2 (polycomb repressive complex 2), aimed at treating prostate cancer.
  • ORIC-114: A brain-penetrant EGFR/HER2 exon 20 inhibitor designed for cancers with specific genetic mutations.

2. Research and Development (R&D)

ORIC invests heavily in R&D to discover and develop new therapies that address unmet medical needs in oncology. The company collaborates with academic institutions and leverages cutting-edge technologies to advance its pipeline.

Business Model

ORIC Pharmaceuticals operates on a research-driven business model, focusing on the discovery, development, and commercialization of novel cancer therapies. The company generates revenue primarily through partnerships, licensing agreements, and potential future product sales. ORIC collaborates with academic institutions and industry partners to accelerate drug development and expand its pipeline. The company’s approach integrates rigorous scientific research, clinical development, and strategic collaborations to bring innovative therapies to market.

Strategic Direction

ORIC is committed to advancing its pipeline of drug candidates and expanding its portfolio of therapies targeting resistance mechanisms in cancer. The company’s strategic priorities include:

  • Pipeline Expansion: ORIC aims to advance its existing drug candidates through clinical trials and explore new therapeutic targets.
  • Partnerships and Collaborations: The company seeks to establish strategic partnerships with academic institutions and biopharmaceutical companies to accelerate drug development.
  • Sustainability Goals: ORIC is dedicated to conducting its operations responsibly and minimizing its environmental impact.
  • Global Reach: The company plans to expand its presence in international markets and address the global burden of cancer.

Competitive Landscape

ORIC operates in a highly competitive biopharmaceutical industry, with several companies focusing on oncology therapeutics and resistance mechanisms. Key competitors include:

  • Mirati Therapeutics: Focused on developing targeted therapies for cancer.
  • Blueprint Medicines: Specializes in precision therapies for genomically defined cancers.
  • Arcus Biosciences: Develops innovative cancer immunotherapies.
  • Relay Therapeutics: Focuses on developing small molecule therapies for cancer.

Despite the competition, ORIC differentiates itself through its focus on resistance mechanisms and its robust pipeline of drug candidates.

Risk Factors

ORIC faces several risks that could impact its business operations and financial performance, including:

  • Clinical Trial Risks: The success of ORIC’s drug candidates depends on the outcomes of clinical trials, which are inherently uncertain.
  • Regulatory Risks: The company must navigate complex regulatory requirements to bring its therapies to market.
  • Market Dependence: ORIC’s revenue is dependent on the successful commercialization of its drug candidates.
  • Supply Chain Disruptions: The company relies on third-party manufacturers and suppliers, which could face disruptions.
  • Competition: Intense competition in the oncology therapeutics market could impact ORIC’s market share.

Recent Developments

ORIC has made significant progress in advancing its pipeline and corporate strategy. Recent developments include:

  • Clinical Trial Updates: ORIC has reported positive preclinical and early clinical data for its drug candidates, including ORIC-101 and ORIC-533.
  • Partnerships: The company has entered into collaborations with leading academic institutions to explore new therapeutic targets.
  • Corporate Strategy: ORIC has strengthened its leadership team and expanded its R&D capabilities to support future growth.
  • Global Developments: The COVID-19 pandemic has posed challenges to clinical trial timelines, but ORIC has adapted its operations to mitigate the impact.

Investment Considerations

Investors considering ORIC Pharmaceuticals should weigh the following strengths and risks:

Strengths

  • Robust pipeline of innovative drug candidates targeting resistance mechanisms in cancer.
  • Experienced leadership team with deep expertise in oncology drug development.
  • Strong focus on R&D and strategic collaborations.

Risks

  • Dependence on clinical trial success and regulatory approvals.
  • High competition in the oncology therapeutics market.
  • Potential supply chain disruptions and operational challenges.

Conclusion

ORIC Pharmaceuticals is well-positioned in the biopharmaceutical industry, with a strong focus on addressing resistance mechanisms in cancer treatment. The company’s innovative pipeline, strategic collaborations, and commitment to R&D provide a solid foundation for future growth. While challenges remain, ORIC’s dedication to advancing oncology therapeutics and addressing unmet medical needs makes it a promising player in the fight against cancer.